Current Radiology Reports

, 4:48 | Cite as

RECIST 1.1, irRECIST 1.1, and mRECIST: How to Do

  • Joern Henze
  • David Maintz
  • Thorsten PersigehlEmail author
Part of the following topical collections:
  1. Oncology


Purpose of Review

This review aims to give a brief update how to do RECIST 1.1, irRECIST 1.1, and mRECIST.

Recent Findings

The revised Response Evaluation Criteria in Solid Tumors (RECIST 1.1) are currently representing the most commonly used and validated response criteria for objective treatment monitoring of conventional chemotherapies in solid tumors. However, with the introduction of novel molecular drugs and local tumor therapies, such as selective transarterial chemoembolization (TACE) at hepatocellular carcinomas (HCC), limitations of the conventional RECIST 1.1 became obvious due to specific response pattern, which are not reflected. Thus, for a comprehensive evaluation of immunotherapeutic agents new immune-related RECIST (irRECIST 1.1) and of selective HCC treatment modified RECIST (mRECIST) criteria have been published.


RECIST 1.1 presents the most used response criteria for conventional chemotherapies in solid tumors. For specific evaluation of immunotherapeutic agents irRECIST 1.1 and of selective HCC treatment mRECIST have been established.


Response criteria RECIST 1.1 irRECIST 1.1 mRECIST 



Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    WHO. WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48, Geneva; 1979.Google Scholar
  2. 2.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16. doi: 10.1093/jnci/92.3.205.CrossRefPubMedGoogle Scholar
  3. 3.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi: 10.1016/j.ejca.2008.10.026.CrossRefPubMedGoogle Scholar
  4. 4.
    Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261–7. doi: 10.1016/j.ejca.2008.10.028.CrossRefPubMedGoogle Scholar
  5. 5.
    • Nishino M, Gargano M, Suda M, Ramaiya NH, Hodi FS. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer. 2014;2:17. doi: 10.1186/2051-1426-2-17. Original publication of irRECIST 1.1.
  6. 6.
    • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi: 10.1055/s-0030-1247132. Original publication of mRECIST for HCC.
  7. 7.
    Hodi FS, O’Day S, McDermott DF, Weber RW, Sosman J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:2255–65. doi: 10.1056/NEJMoa1207290.CrossRefGoogle Scholar
  8. 8.
    Spiro J, Maintz D, Persigehl T. Responsekriterien bei malignem Melanom—RECIST und irRC. Radiologe. 2015;2:127–35. doi: 10.1007/s00117-014-2763-y.CrossRefGoogle Scholar
  9. 9.
    Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20. doi: 10.1158/1078-0432.CCR-09-1624.CrossRefPubMedGoogle Scholar
  10. 10.
    Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936–43. doi: 10.1158/1078-0432.CCR-13-0895.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kim MN, Kim BK, Han K-H, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol. 2015;9:335–48. doi: 10.1586/17474124.2015.959929.CrossRefPubMedGoogle Scholar
  12. 12.
    Hyun D, Shin SW, Cho SK, Park KB, Park HS, et al. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol. 2015;56:1437–45. doi: 10.1177/0284185114560937.CrossRefPubMedGoogle Scholar
  13. 13.
    Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16–22. doi: 10.3109/03009734.2012.729104.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shim JH, Lee HC, Kim S-O, Shin YM, Kim KM, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708–18. doi: 10.1148/radiol.11110282.CrossRefPubMedGoogle Scholar
  15. 15.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118:147–56. doi: 10.1002/cncr.26255.CrossRefPubMedGoogle Scholar
  16. 16.
    ACR. American College of Radiology - Liver Imaging Reporting and Data System version 2014. 2014.

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of RadiologyUniversity Hospital of CologneCologneGermany

Personalised recommendations